Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
A staggering 65% of the TB cases in India are in the 15-45 age group
Data to establish the safety profile and human dose of vaccine candidate
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
